Focusing on people at high risk of the new crown, this drug can effectively reduce the risk of severe disease in the population

So far, the prevention and control of the new crown virus epidemic seems to have become the norm of our lives, in addition to continuing to strengthen prevention and control, the treatment of the new crown has become a common
concern in the global medical field.
November 6, 2022, "Join hands to overcome difficulties" The new crown disease prevention and control seminar was held at the 5th CIIE, and comprehensive discussions
were held on topics such as the timing of clinical anti-new coronavirus treatment and the treatment of infection in high-risk groups of severe new crown disease.

Peng Zhenke, President of Pfizer's Global Biopharmaceutical Business Group China, said: "Pfizer's mission is to 'bring breakthroughs and innovations that change patients' lives', and we will uphold the principle of 'science wins'.
to provide innovative treatment options for Chinese patients, continue to fight infection with clinicians, cooperate with the Chinese government and all sectors of society, improve access to innovative drugs, and help realize
the grand vision of 'Healthy China 2030'.
" ”

Pay attention to the high-risk factors of the new crown and pay attention to the treatment of high-risk groups of severe new crown disease

The "Diagnosis and Treatment Plan for Novel Coronavirus Pneumonia (Trial Ninth Edition)" pointed out that the elderly over 60 years old, chronic kidney disease, diabetes, cardiovascular and chronic lung diseases, obesity (body mass index ≥ 30), heavy smokers, etc.
are all high-risk factors for the development of severe / critical illness of the new crown
。

In February this year, in accordance with the relevant provisions of the Drug Administration Law, the State Medical Products Administration conducted an emergency review and approval in accordance with the special approval procedure for drugs, and conditionally approved the combination packaging of Pfizer's new coronavirus treatment drug nematevir tablets/ritonavir tablets (i.
e.
Paxlovid™ Import registration
.

Paxlovid is a protease inhibitor consisting of
two main components, nirmatrelvir and ritonavir.
Among them, nirmatrelvir is a new coronavirus 3CL protease inhibitor, which can disrupt the subsequent RNA replication process of the new coronavirus by blocking the activity of the new coronavirus 3CL protease
。 Another ingredient, ritonavir, allows nirmatrelvir to remain active in the body for longer periods of time and better fight viruses
.

In March this year, China's "Diagnosis and Treatment Plan for Novel Coronavirus Pneumonia (Trial Ninth Edition)" recommended Paxlovid in antiviral treatment for adults
with mild and ordinary types with high-risk factors for progression to severe disease within 5 days of onset.

Focus on real-world research and work together to overcome difficulties

In academic research, real-world research analysis of the treatment of high-risk patients has also attracted attention
in the field of medical research and treatment worldwide.
In the face of the challenges of diagnosis and treatment of new crown diseases, the majority of medical workers in China continue to actively explore the diagnosis and treatment strategies of new crown diseases, actively carry out scientific research and accumulate valuable clinical data, publish research results in authoritative journals of world-renowned medical journals such as The Lancet, and share academic with
the medical community around the world.

Zheng Junhua, Secretary of the Party Committee of Renji Hospital of Shanghai Jiao Tong University School of Medicine, served as the chief commander
of the Shanghai World Expo Exhibition and Convention Center Fangcang Hospital, the New International Expo Center Fangcang Hospital, and the Sanya Third-party Cabin Hospital.
Secretary Zheng pointed out that in the face of the reality of China's large elderly population base and many combined basic diseases, the risk of new crown infection in the control of the population cannot be relaxed
.

In July this year, the director team of the Department of Rheumatology and the director of the Department of Critical Care Medicine of Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine published an online publication entitled "Paxlovid" in the international authoritative medical journal "The Lancet: Infectious Diseases" on July 14 For Immunosuppressive Hospitalized Patients with SARS-CoV-2 Infection".

Professor Feng Zhanhui from the Affiliated Hospital of Guizhou Medical University published 13 studies in J INFECT (IF=38.
637) in October 186306 Meta-analysis
of patient efficacy and safety.

At present, Paxlovid is still a key drug for the treatment of new crown infection, which can effectively reduce the risk of severe disease in people, such as individuals with comorbidities, unvaccinated or weakened vaccine-induced immunity
.